ALLO

1.42

2.07% -0.03

Dopo l'orario di chiusura: 1.39 -0.03 -2.11%

Allogene Therapeutics Inc (ALLO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.45

Aprire:

$1.41

Volume 24 ore:

2.18M

Relative Volume:

0.42

Capitalizzazione di mercato:

$310.69M

Reddito:

$95,000

Utile/perdita netta:

$-327.27M

Rapporto P/E:

-0.6698

EPS:

-2.12

Flusso di cassa netto:

$-239.25M

1 W Prestazione:

-0.70%

1M Prestazione:

-12.35%

6M Prestazione:

-49.29%

1 anno Prestazione:

-59.08%

Intervallo 1D:

$1.39

$1.49

Intervallo di 1 settimana:

$1.375

$1.53

Portata 52W:

$1.23

$3.78

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Nome

Allogene Therapeutics Inc

Settore

Healthcare (1155)

Industria

Biotechnology (677)

Telefono

(650) 457-2700

Indirizzo

210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO

Dipendente

361

Cinguettio

@AllogeneTx

Prossima data di guadagno

2025-03-04

Ultimi documenti SEC

ALLO's Discussions on Twitter

Confronta ALLO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ALLO Allogene Therapeutics Inc	1.42	310.69M	95,000	-327.27M	-239.25M	-2.12
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-03-14	Aggiornamento	Citizens JMP	Mkt Perform → Mkt Outperform
2024-08-08	Ripresa	Oppenheimer	Outperform
2024-05-31	Iniziato	Piper Sandler	Overweight
2024-01-05	Downgrade	Guggenheim	Buy → Neutral
2024-01-05	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	Iniziato	Citigroup	Buy
2023-06-26	Ripresa	Oppenheimer	Outperform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-01-24	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-06	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-12-12	Downgrade	BofA Securities	Buy → Underperform
2022-08-10	Downgrade	Raymond James	Outperform → Mkt Perform
2022-07-15	Aggiornamento	Goldman	Neutral → Buy
2022-06-03	Iniziato	Robert W. Baird	Neutral
2022-02-28	Reiterato	B. Riley Securities	Buy
2021-10-20	Iniziato	Cowen	Outperform
2021-10-08	Downgrade	Goldman	Buy → Neutral
2021-10-08	Downgrade	Stifel	Buy → Hold
2021-09-23	Aggiornamento	Raymond James	Mkt Perform → Outperform
2021-06-21	Ripresa	Jefferies	Buy
2021-05-20	Aggiornamento	Truist	Hold → Buy
2021-05-14	Iniziato	B. Riley Securities	Buy
2021-01-26	Aggiornamento	Stifel	Hold → Buy
2020-12-10	Ripresa	H.C. Wainwright	Buy
2020-11-24	Iniziato	BofA Securities	Buy
2020-10-23	Iniziato	RBC Capital Mkts	Outperform
2020-06-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-29	Reiterato	H.C. Wainwright	Buy
2020-05-19	Aggiornamento	ROTH Capital	Neutral → Buy
2020-05-15	Aggiornamento	Guggenheim	Neutral → Buy
2020-05-14	Reiterato	H.C. Wainwright	Buy
2020-05-14	Downgrade	SunTrust	Buy → Hold
2020-04-13	Iniziato	SunTrust	Buy
2020-03-13	Iniziato	H.C. Wainwright	Buy
2020-03-05	Iniziato	Stifel	Hold
2020-02-24	Iniziato	Berenberg	Hold
2019-12-18	Iniziato	JMP Securities	Mkt Outperform
2019-11-04	Iniziato	Canaccord Genuity	Buy
2019-08-09	Iniziato	BTIG Research	Buy
2019-06-05	Iniziato	ROTH Capital	Neutral
2019-05-31	Iniziato	Guggenheim	Neutral
2019-05-23	Iniziato	Stifel	Hold
2019-03-29	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie

Apr 10, 2025

Allogene received FDA Fast-track statuses for its dual CAR-Therapy - MSN

Apr 10, 2025

FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug - MSN

Apr 10, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Allogene stock hits 52-week low at $1.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 08, 2025

FDA Grants Three Fast Track Tags To Allogene's Autoimmune Disease Drug - Barchart.com

Apr 08, 2025

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy By Investing.com - Investing.com South Africa

Apr 07, 2025

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Apr 07, 2025

Allogene's ALLO-329 Granted Three FDA Fast Track Designations - Nasdaq

Apr 07, 2025

Allogene Gets FDA Fast Track Designations for ALLO-329 in Autoimmune Diseases - marketscreener.com

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (Ftd) For Allo-329 - MarketScreener

Apr 07, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - The Manila Times

Apr 07, 2025

FDA grants fast track status to Allogene’s autoimmune therapy - Investing.com

Apr 07, 2025

Groundbreaking Triple FDA Fast Track: Allogene's New CAR T Targets Multiple Autoimmune Diseases - Stock Titan

Apr 07, 2025

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline - Investing.com

Apr 01, 2025

Allogene stock plunges to 52-week low of $1.32 amid steep annual decline By Investing.com - Investing.com South Africa

Apr 01, 2025

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa

Mar 19, 2025

H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India

Mar 19, 2025

Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com

Mar 17, 2025

Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India

Mar 17, 2025

Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech

Mar 17, 2025

Mar 16, 2025

Allogene upgraded at Citizens after Q4 update - MSN

Mar 16, 2025

Mar 15, 2025

Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 15, 2025

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 15, 2025

Mar 14, 2025